Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1956 1
1957 2
1960 5
1961 3
1962 1
1963 3
1964 5
1965 2
1966 1
1967 6
1968 4
1969 3
1970 3
1971 3
1972 3
1973 2
1974 3
1975 3
1976 3
1977 5
1979 1
1982 2
1984 1
1985 2
1993 2
1994 1
1997 2
1999 6
2000 5
2001 5
2002 3
2003 5
2004 7
2005 8
2006 7
2007 7
2008 3
2009 3
2010 7
2011 4
2012 11
2013 13
2014 11
2015 11
2016 12
2017 26
2018 15
2019 31
2020 21
2021 15
2022 12
2023 19
2024 17
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Results by year

Filters applied: . Clear all
Page 1
Guidelines for the Diagnosis and Clinical Management of Cavernous Malformations of the Brain and Spinal Cord: Consensus Recommendations Based on a Systematic Literature Review by the Alliance to Cure Cavernous Malformation Clinical Advisory Board Experts Panel.
Akers AL, Albanese J, Alcazar-Felix RJ, Al-Shahi Salman R, Awad IA, Connolly ES, Danehy A, Flemming KD, Gordon E, Hage S, Kim H, Lanzino G, Lee CH, McCormick PC, Mabray MC, Marchuk DA, Smith E, Smith KM, Srivastava S, Taylor JM, Vadivelu S. Akers AL, et al. Among authors: flemming kd. Neurosurgery. 2025 May 21. doi: 10.1227/neu.0000000000003459. Online ahead of print. Neurosurgery. 2025. PMID: 40396744
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial.
Awad IA, Alcazar-Felix RJ, Stadnik A, Kinkade S, Jhaveri A, Lee J, Hage S, Iqbal J, Polster SP, Shenkar R, Treine K, McBee N, Ostapkovich N, Lane K, Liao JK, Sorrentino M, Lee C, Flemming KD, Girard R, Carroll TJ, Thompson RE, Hanley DF. Awad IA, et al. Among authors: flemming kd. Lancet Neurol. 2025 Apr;24(4):295-304. doi: 10.1016/S1474-4422(25)00036-5. Lancet Neurol. 2025. PMID: 40120614 Clinical Trial.
Clinical and genetic characterization of a progressive RBL2-associated neurodevelopmental disorder.
Aughey GN, Cali E, Maroofian R, Zaki MS, Pagnamenta AT, Ali Z, Abdulllah U, Rahman F, Menzies L, Shafique A, Suri M, Roze E, Aguennouz M, Ghizlane Z, Saadi SM, Fatima A, Cheema HA, Anjum MN, Morel G, Robin S, McFarland R, Altunoglu U, Kraus V, Shoukier M, Murphy D, Flemming K, Yttervik H, Rhouda H, Lesca G, Chatron N, Rossi M, Murtaza BN, Ur Rehman M, Lord J, Giacopuzzi E, Hayat A, Siraj M, Shervin Badv R, Seo GH, Beetz C, Kayserili H, Krioulie Y, Chung WK, Naz S, Maqbool S, Chandler KE, Kershaw CJ, Wright T, Banka S, Gleeson JG, Taylor JC, Efthymiou S, Baig SM, Severino M, Jepson JEC, Houlden H. Aughey GN, et al. Among authors: flemming k. Brain. 2025 Apr 3;148(4):1194-1211. doi: 10.1093/brain/awae363. Brain. 2025. PMID: 39692517 Free PMC article.
326 results